Integration with Other ME/CFS Pathophysiology
Gastrointestinal dysfunction interconnects with other ME/CFS mechanisms (these connections are synthesized into comprehensive multi-system models in Chapter Integrative Models and Multi-System Pathophysiology):
Immune dysfunction (Chapter Immune System Dysfunction): Intestinal permeability drives LPS-mediated immune activation; GALT dysregulation affects systemic immunity
Autonomic dysfunction (Chapter Neurological and Neurocognitive Dysfunction): Vagal impairment causes gastroparesis and MMC dysfunction; dysautonomia and GI symptoms bidirectionally reinforce each other. A specific gut–vagal mechanism may operate through enterochromaffin cell serotonin release affecting vagal afferent signaling (Section Replication Status: Not Yet Replicated), with potential downstream effects on cardiovascular autonomic function (Chapter Cardiovascular Dysfunction)
MCAS (Section Prospective Phenotyping as Harm Reduction): Bidirectional microbiome–mast cell regulation operates through butyrate-mediated epigenetic suppression and dysbiosis-driven histamine/LPS activation (Microbiome–Mast Cell Bidirectional Regulation, Section Tissue-Resident T Cell Dysfunction Links Gut and Systemic Immunity in ME/CFS); mast cells in gut mucosa affect motility and permeability, with potential interactions with SIBO
Energy metabolism (Chapter Energy Metabolism and Mitochondrial Function): Butyrate deficiency reduces colonocyte energy; malabsorption impairs nutrient availability for mitochondrial function
Neurological symptoms: Gut-brain axis dysfunction contributes to cognitive impairment, mood disturbance, and autonomic symptoms
1 Cross-Condition Evidence: ME/CFS, Long COVID, Fibromyalgia
Butyrate deficiency shows evidence of cross-condition consistency across ME/CFS, Long COVID, and fibromyalgia. Kim 2026 documented shared butyrate deficiency between Long COVID and ME/CFS patients, suggesting common pathophysiological mechanisms. Watai 2025 environmental sensitivity illnesses demonstrate shared butyrate deficiency pattern across related conditions. Wang 2024 clinical evidence confirms consistency across these conditions. These findings support broader relevance of butyrate mechanisms in functional disorders.
Critical unresolved questions:
- Does dysbiosis cause ME/CFS symptoms, or is it a consequence of the disease?
- Can correcting microbiome alterations improve ME/CFS outcomes?
- Which comes first: autonomic dysfunction causing dysmotility, or gut dysfunction driving autonomic symptoms?
- Would microbiome-targeted therapies be disease-modifying or merely symptomatic?
Answering these questions requires interventional studies with objective outcome measures beyond symptom questionnaires.
Butyrate provides approximately 70% of colonocyte energy through beta-oxidation. ME/CFS patients show deficient butyrate production (Achievement Deficient Butyrate-Producing Capacity) (C. Guo et al. 2023), which may trigger a systemic energy drain cascade: colonocytes draw glucose from systemic circulation → reduced glucose availability for brain and muscle → compensatory glycolysis → lactate accumulation → mitochondrial stress. This colonocyte-systemic energy competition provides a novel mechanistic pathway linking gut dysbiosis to ME/CFS energy dysregulation findings, including hypometabolic state (Naviaux et al. 2016) and acyl-carnitine reductions (Germain et al. 2020).
Falsifiable Prediction: Oral butyrate supplementation (tributyrin 1g TID) should increase peripheral blood glucose during fasting by reducing colonocyte glucose demand; concurrent RBC carnitine should normalize within 8 weeks as systemic energy stress resolves.
::: {.callout-important .env-hypothesis} ### Hypothesis: Butyrate-GPR41/43 Vagal Signaling Deficit Explains Orthostatic Intolerance Subtype
Butyrate directly activates vagal afferents via GPR41/43 receptors (Hodgkinson et al. 2023). ME/CFS patients with butyrate deficiency may experience reduced vagal afferent stimulation, which diminishes cholinergic anti-inflammatory pathway (CAP) activation specifically during postural stress. This deficit could explain the high prevalence of POTS comorbidity and orthostatic intolerance in ME/CFS (Hodgkinson et al. 2023).
Falsifiable Prediction: Peripheral blood mononuclear cells from ME/CFS patients should show reduced GPR41/43 expression; butyrate supplementation should increase GPR41/43 expression and improve orthostatic tolerance (head-up tilt test) within 6 weeks. :::
::: {.callout-important .env-hypothesis} ### Hypothesis: Butyrate-Tryptophan Competition Creates Cerebral Serotonin Paradox
Butyrate-producing bacteria (e.g., Faecalibacterium prausnitzii) consume complex carbohydrates that would otherwise feed tryptophan-metabolizing bacteria. In ME/CFS, butyrate deficiency may shift the microbiome toward tryptophan-degrading bacteria, reducing tryptophan availability for both gut serotonin production (enterochromaffin cells) and brain serotonin synthesis. This competition mechanism explains the paradoxical peripheral serotonin depletion reported in ME/CFS patients (Simonato et al. 2021) despite central serotonergic hyperactivity observed in some models (Lee et al. 2024) (C. Guo et al. 2023).
Falsifiable Prediction: ME/CFS patients should show increased fecal tryptophan-metabolizing bacteria (e.g., Enterobacteriaceae, Clostridia spp.) and reduced free tryptophan levels; butyrate supplementation should restore tryptophan availability and normalize CSF serotonin metabolites. :::
2 Gut-Brain Metabolic Coupling {#sec-butyrate-tryptophan-paradox}
The preceding sections establish that ME/CFS patients show reduced butyrate-producing bacteria (Achievement Deficient Butyrate-Producing Capacity), disrupted tryptophan metabolism, and impaired gut-brain axis signaling (Section Replication Status: Not Yet Replicated). Separately, evidence from neuroimaging demonstrates brain hypometabolism in ME/CFS (see Chapter Neurological and Neurocognitive Dysfunction). The following speculation proposes a mechanistic link between these observations.
In ME/CFS, a dysbiotic microbiome may actively divert energy substrates away from the central nervous system, contributing to or worsening brain hypometabolism and cognitive dysfunction. This “energy theft” operates through several convergent mechanisms:
Bacterial Substrate Competition. The human gut harbors approximately $ 10^{13}$ bacteria, collectively constituting a metabolically active organ that consumes host nutrients. Under normal conditions, commensal bacteria provide net metabolic benefits—fermenting indigestible fiber into short-chain fatty acids, synthesizing vitamins, and supporting immune homeostasis. However, when dysbiosis shifts the community toward pathobionts and away from mutualists, this metabolic balance may reverse. Pathogenic and opportunistic bacteria preferentially consume simple sugars (glucose, amino acids) that would otherwise be absorbed by the host for systemic distribution, including to the brain (C. J. Guo et al. 2025). In ME/CFS, where total energy availability is already compromised (Chapter Energy Metabolism and Mitochondrial Function), even modest bacterial diversion of substrates could meaningfully reduce CNS energy supply.
Butyrate Deficiency and Brain Energy. Butyrate is not merely a colonocyte fuel—it crosses the blood-brain barrier and serves as a preferred energy substrate for astrocytes, outcompeting acetate in cerebral cortical tissue (Ameen et al. 2025). Astrocytes are central to the brain’s metabolic support network, providing neurons with lactate and other substrates via the astrocyte-neuron lactate shuttle. The well-documented butyrate producer deficiency in ME/CFS (Achievement Deficient Butyrate-Producing Capacity) therefore has implications beyond gut health: reduced circulating butyrate may deprive astrocytes of a key energy substrate, impairing their capacity to support neuronal metabolism.
Tryptophan Diversion. Gut bacteria metabolize tryptophan through multiple pathways, reducing systemic availability of this essential amino acid. In ME/CFS, dysbiosis-associated kynurenine pathway hyperactivation diverts tryptophan away from serotonin synthesis (see Section Replication Status: Not Yet Replicated and (Kavyani et al. 2022) (Abujrais, Vallianatou, and Bergquist 2024)). Beyond serotonin depletion, this diversion depletes NAD+ precursors via quinolinic acid accumulation, further compromising cellular energy metabolism in the brain.
Inflammation Tax. Dysbiosis-driven intestinal permeability (Achievement Evidence of Bacterial Translocation in ME/CFS) results in LPS translocation and chronic low-grade endotoxemia. The immune response to translocated bacterial products imposes a significant metabolic cost: pro-inflammatory cytokine production, acute phase protein synthesis, and immune cell activation collectively consume glucose and amino acids that would otherwise support CNS function (El-Sehrawy et al. 2025). This “inflammation tax” compounds the direct substrate competition, creating a double burden on the already constrained energy budget.
Testable Predictions.
- Dysbiosis severity (measured by reduced butyrate-producer abundance or increased pathobiont load) should correlate with degree of CNS hypometabolism on FDG-PET imaging.
- Microbiome restoration interventions (FMT, targeted probiotics; see Section Probiotic Cautions and Speculation FMT for ME/CFS) should improve cognitive function, with effect size proportional to microbiome normalization.
- Fecal butyrate levels should correlate with plasma butyrate and, in turn, with brain metabolic markers (MR spectroscopy NAA/Cr ratios or FDG-PET regional uptake).
- Post-prandial cognitive worsening (commonly reported by patients as “food coma” or post-meal brain fog) should correlate with markers of bacterial fermentation and small intestinal bacterial load.
- Periods of reduced caloric intake or fasting may temporarily improve cognitive clarity by reducing bacterial substrate availability—though this must be weighed against the risks of caloric restriction in an energy-depleted condition.
Treatment Implications. This framework suggests that cognitive symptoms in ME/CFS may be partially addressable through microbiome-targeted interventions:
- Targeted probiotics: Supplementation with butyrate-producing strains (F. prausnitzii, E. rectale) to restore SCFA production and potentially brain butyrate supply.
- Prebiotics: Dietary fiber substrates (resistant starch, inulin) that selectively feed butyrate producers.
- SIBO treatment: Reducing small intestinal bacterial overgrowth (Section Gastrointestinal Dysfunction) may decrease proximal glucose competition.
- Direct butyrate supplementation: Oral sodium butyrate or tributyrin to bypass microbial production deficits.
Limitations.
- The correlation between dysbiosis and cognitive symptoms does not establish causation—both may result from a common upstream mechanism (e.g., autonomic dysfunction reducing gut motility).
- Quantitative modeling of bacterial substrate consumption relative to host needs has not been performed; the “theft” may be quantitatively trivial compared to total host energy flux.
- Current evidence for butyrate as a brain fuel comes primarily from animal models (Ameen et al. 2025); human relevance at physiological concentrations remains to be confirmed.
- Individual variation in microbiome composition, diet, and metabolic rate makes population-level predictions difficult.
Certainty: 0.40. This is a speculative integrative hypothesis synthesizing established individual findings into a novel mechanistic framework. Direct validation through the testable predictions above is needed before clinical application.
3 The Oral Microbiome: An Underexplored Compartment
ME/CFS microbiome research has focused almost exclusively on the intestinal tract. The oral microbiome—a distinct ecological niche harboring over 700 bacterial species—remains virtually unstudied in ME/CFS, despite well-established evidence that oral dysbiosis drives systemic inflammation in other conditions (Hasan et al. 2025) (G. Hajishengallis and Chavakis 2021).
Periodontitis affects approximately 47% of U.S. adults (Hasan et al. 2025). The disease provides a chronic portal for bacterial entry into the bloodstream: periodontal pathogens such as Porphyromonas gingivalis and Aggregatibacter actinomycetemcomitans disseminate via ulcerated pocket epithelium, triggering systemic elevations in CRP, IL-6, TNF-α, and IL-1β—the same inflammatory mediators consistently elevated in ME/CFS (Chapter Immune System Dysfunction) (Hasan et al. 2025) (George Hajishengallis 2015). Notably, P. gingivalis functions as a “keystone pathogen,” manipulating complement and TLR crosstalk to disable immune clearance while sustaining inflammation (George Hajishengallis 2015)-–a strategy that could compound the immune dysregulation already present in ME/CFS.
Three pathways make the oral-systemic connection potentially relevant to ME/CFS:
- Endothelial dysfunction: Periodontal bacteremia promotes atherosclerotic plaque formation and impairs endothelial function (Hasan et al. 2025) (Tattar, Dias Carvalho da Costa, and Neves 2025), overlapping with the vascular dysfunction documented in ME/CFS (Chapter Cardiovascular Dysfunction).
- Neuroinflammation: P. gingivalis gingipains cross the blood-brain barrier, promote amyloid-β accumulation, and drive microglial activation (Dominy et al. 2019). These mechanisms parallel the neuroinflammation documented in ME/CFS (Chapter Neurological and Neurocognitive Dysfunction).
- Autoimmunity via citrullination: P. gingivalis citrullinates host peptides, generating neoantigens that trigger autoimmune responses—the established “two-hit” model for rheumatoid arthritis (Hasan et al. 2025). Whether citrullination could contribute to the GPCR autoantibodies observed in ME/CFS (Section Cardiac Function) is unknown but mechanistically plausible.
No study has assessed periodontal disease prevalence, oral microbiome composition, or oral-origin systemic inflammatory burden in ME/CFS patients. Several factors suggest this gap deserves attention:
- Severe ME/CFS patients report inability to maintain oral hygiene (teeth brushing described as exhausting; Section The Devastating Reality of Severe ME/CFS), creating conditions favourable for periodontal disease progression.
- The resulting chronic low-grade bacteremia would add to the systemic inflammatory load from intestinal barrier dysfunction (Section AhR Evidence Is Subgroup-Specific and Lacks Immune-Readout Confirmation), potentially compounding the “inflammation tax” described in Speculation Gut-Brain Energy Theft Hypothesis.
- Periodontal treatment is a modifiable intervention: scaling and root planing reduces systemic CRP and IL-6 (Tattar, Dias Carvalho da Costa, and Neves 2025), and could theoretically reduce inflammatory burden in ME/CFS without pharmacological intervention.
Key research questions:
- Is periodontal disease prevalence elevated in ME/CFS compared to age/sex-matched controls?
- Does oral microbiome composition differ in ME/CFS, and does it correlate with systemic inflammatory markers?
- Does periodontal treatment reduce systemic inflammatory markers or improve symptoms in ME/CFS patients?
- Is there a severity gradient, with more severe patients (who have greater self-care limitations) showing worse periodontal status and higher oral-origin inflammatory burden?
In severe ME/CFS, a self-reinforcing cycle may operate between disability and oral health deterioration:
- Severe fatigue and post-exertional malaise limit capacity for dental hygiene (teeth brushing, flossing, dental visits)
- Neglected oral hygiene permits periodontal disease development and progression
- Periodontal disease establishes chronic bacteremia and systemic inflammation (elevated TNF-α, IL-1β, IL-6, CRP) (Hasan et al. 2025) (G. Hajishengallis and Chavakis 2021)
- Additional inflammatory burden worsens ME/CFS symptoms (fatigue, cognitive dysfunction, immune activation)
- Worsened symptoms further reduce self-care capacity, completing the cycle
This cycle is notable because it is entirely modifiable through external intervention: caregiver-assisted oral hygiene, domiciliary dental services, or professional dental care adapted for energy-limited patients. If the cycle contributes meaningfully to symptom burden, periodontal management represents a low-risk, non-pharmacological intervention that could reduce systemic inflammation.
Testable predictions:
- ME/CFS symptom severity should correlate with periodontal disease markers (pocket depth, attachment loss, bleeding on probing) after controlling for age, smoking, and diabetes.
- Implementation of assisted oral hygiene protocols in severe ME/CFS patients should reduce systemic CRP and IL-6 within 3–6 months.
- Periodontal treatment in ME/CFS patients with comorbid periodontitis should produce greater symptom improvement than in ME/CFS patients without periodontitis.
Limitations:
- The cycle is hypothesised by analogy from periodontitis research in other chronic conditions; no ME/CFS-specific data exist.
- The inflammatory contribution from oral sources may be quantitatively trivial compared to gut-derived endotoxemia and other inflammatory sources in ME/CFS.
- Dental procedures themselves can trigger PEM in severe patients, complicating the intervention.
Certainty: 0.30. The individual links (disability → poor oral hygiene; periodontal disease → systemic inflammation) are well-established, but the complete cycle and its clinical significance in ME/CFS are entirely speculative.
Gut-barrier repair may be optimised when butyrate dosing aligns with circadian patterns of HDAC inhibition and vagal signalling. Preclinical evidence suggests that epigenetic regulators (HDACs) and vagal afferent responses exhibit circadian oscillations in expression and sensitivity (Smith 2023). If butyrate’s barrier-protective effects are mediated through these circadian-regulated pathways, the timing of supplementation could significantly influence efficacy:
- Hypothesis:: Administering butyrate during the biologically active phase of vagal tone and HDAC inhibition may enhance colonocyte energy utilisation, tight junction maintenance, and systemic anti-inflammatory signalling.
- Mechanistic pathway:: Butyrate → GPR41/43 agonism → vagal efferent stimulation → hepatic insulin sensitisation + anti-inflammatory tone. Circadian modulation of GPR41/43 expression or coupling efficiency could amplify or diminish this pathway.
- Testable predictions:: (1) Fasting vs. fed butyrate administration produces different serum butyrate peaks and circadian cortisol interactions; (2) Biomarkers of gut barrier integrity (lactulose/mannitol ratio, fecal calprotectin) show circadian patterns; (3) Early-morning vs. evening butyrate dosing produces differential effects on vagal tone and inflammatory markers.
Limitations:
- Circadian modulation of butyrate metabolism has not been demonstrated in humans.
- Existing butyrate dosing regimens (500 mg–2 g TID with meals) already influence circadian eating patterns.
- Individual differences in chronotype may make uniform timing impractical.
Certainty: 0.40. This integrates preclinical circadian biology with butyrate mechanisms. Human data are needed to confirm timing effects.
Combining botanical compounds that stimulate MUC2 production with butyrate may produce synergistic effects on gut barrier integrity. The MUC2 layer is the primary mucosal barrier protecting epithelial surfaces from luminal insult; butyrate promotes tight junction formation while MUC2 provides physical coating. Preliminary evidence suggests the following botanical agents may enhance MUC2 synthesis:
- Zinc carnosine (L-carnosine zinc complex): Antioxidant and mucosal healing properties; shown to increase mucus production in gastric ulcer models (Hongo 2021).
- Berberine: AMPK activator; improves intestinal barrier function and reduces permeability in experimental colitis (Zhang 2022).
- Aloe vera: Mucopolysaccharide content; soothing effect on gastrointestinal mucosa (Mazar 2020).
- Quercetin: Tight junction stabiliser; inhibits ZO-1 degradation in intestinal epithelial cells (Gao 2021).
Proposed mechanism:: Zinc carnosine enhances mucus layer thickness, berberine strengthens tight junctions, aloe vera provides a soothing mucosal surface, and quercetin protects junction proteins from proteolytic degradation. Butyrate, delivered separately or as part of a combined protocol, directly fuels colonocyte mitochondria and activates GPR41/43-mediated vagal signalling. Together, they may create a layered barrier (mucus + epithelial + tight junctions) that is more resilient than either intervention alone.
Potential clinical application:: For patients with refractory gut barrier dysfunction despite butyrate supplementation, a botanical-MUC2 combination may address an unmet need by targeting both the physical coating (mucus) and the epithelial attachment (tight junctions).
Limitations:
- No human studies have tested this specific combination.
- Individual botanical compounds have multiple mechanisms; additive effects are not guaranteed.
- Herbal preparations vary in standardisation and purity; interaction risks exist.
Certainty: 0.35. The components each have mechanistic support in gut barrier contexts, but the combination is entirely speculative.
Existing ME/CFS energy models (e.g., glucose competition, lactate shuttling) focus on systemic metabolic competition between gut bacteria and host cells. However, butyrate-colonocyte energy metabolism represents a specialised niche: butyrate is a preferred fuel for colonocytes, but excessive butyrate production by dysbiotic microbes could theoretically outcompete host colonocytes for this substrate, particularly under energy-depleted conditions.
This raises a question about whether butyrate-colonocyte energy competition should be incorporated into formal energy-equation models for ME/CFS:
- Substrate competition variable: Should a parameter be added representing colonocyte glucose demand versus butyrate availability?
- Threshold effects: Does excessive bacterial butyrate production shift colonocyte energy metabolism toward anaerobic pathways, creating a bottleneck for systemic energy export?
- Model complexity: Adding this competition may significantly increase model complexity; does the added explanatory value justify the complexity?
Key research needs:
- Quantitative data on colonocyte butyrate utilisation rates under different microbiome conditions.
- Measurement of intra-colonic butyrate gradients to assess competition dynamics.
- Experimental or observational data linking bacterial butyrate overproduction to host colonocyte metabolic impairment.
Certainty: 0.50. This is a conceptual modelling question with moderate evidence for its relevance, but quantitative parameters remain undefined.
Certainty: 0.10. Systemic exosomes can reach the intestinal lumen via transcytosis; dietary and microbial metabolites influence exosome biogenesis in host cells. A bidirectional axis may exist where (a) systemically administered therapeutic exosomes alter gut microbiome composition via luminal delivery, and (b) gut microbiome-derived metabolites (SCFAs, tryptophan) modulate host exosome production and cargo. This is entirely speculative — no exosome-microbiome interaction data exist in ME/CFS or any human population. Included as a research curiosity only, not a mechanistic claim.
Certainty: 0.30. Intermittent fasting or prolonged fasting may induce endoplasmic reticulum (ER) stress in intestinal epithelial cells (IECs) of ME/CFS patients, triggering the unfolded protein response (UPR) in a gut-specific manner that propagates to hepatic inflammation via the gut-liver axis. Fasting deprives IECs of luminal nutrients, particularly butyrate (their preferred fuel, Section Gut Microbiome Alterations), forcing metabolic reliance on glutamine and ketone bodies. In energy-compromised ME/CFS IECs, this fuel switch may exceed the mitochondrial capacity, producing ER stress via ATP insufficiency for protein folding.
Mechanism. IECs are high-turnover cells with substantial protein synthesis demands (digestive enzymes, mucins, tight junction proteins). During fasting, the loss of butyrate as primary energy source shifts metabolism to glutamine oxidation. If mitochondrial reserve is insufficient (consistent with documented ME/CFS mitochondrial dysfunction, Chapter Energy Metabolism and Mitochondrial Function), ATP production falls short of protein folding demand, causing: (1) unfolded protein accumulation in the ER → PERK/eIF2alpha activation; (2) IRE1alpha-XBP1s pathway activation driving inflammatory cytokine production (IL-6, TNF-alpha); (3) ATF6-mediated CHOP expression → IEC apoptosis if UPR fails to restore homeostasis. Apoptotic IECs release DAMPs (HMGB1, ATP) into the portal circulation, activating hepatic Kupffer cells via TLR4 and NLRP3 → liver inflammation → systemic cytokine elevation. HMGB1’s redox-dependent pro-inflammatory activity (disulfide-HMGB1 signals via TLR4 while fully reduced HMGB1 is chemotactic) provides a mechanistic link between fasting-induced ER stress and the type of inflammatory output observed (Ibrahim, Wasim, and Rahman 2026) (Chen et al. 2026). The liver responds by producing acute-phase proteins (CRP, serum amyloid A) that further impair systemic energy metabolism.
ME/CFS context. ME/CFS patients often report that fasting improves cognitive clarity temporarily (patient-reported — not yet studied formally), but prolonged fasting or caloric restriction triggers PEM-like deterioration. This biphasic response may reflect initial UPR adaptation (ATF4-driven metabolic flexibility improvement) followed by ER stress decompensation when mitochondrial reserve runs out. The gut-liver axis connection also links to hepatic insulin resistance (Section Insulin and Glucose Metabolism in Chapter Endocrine and Metabolic Dysfunction) — liver inflammation from IEC-derived DAMPs would impair hepatic gluconeogenesis regulation and contribute to the metabolic inflexibility documented in ME/CFS.
Falsifiable predictions. (1) ME/CFS IECs (organoid cultures from patient biopsies) will show elevated UPR markers (p-eIF2alpha, XBP1s, CHOP) and reduced ATP content compared to controls under fasting-mimicking conditions (low glucose, low butyrate). (2) ME/CFS plasma will show elevated IEC-derived DAMPs (I-FABP, REG3alpha) during prolonged fasting (>16 h) but not after short-term fasting (12 h), correlating with UPR markers in blood. (3) Portal vein-equivalent markers (GLP-2, FGF19) in ME/CFS will show an altered fasting-response profile consistent with IEC ER stress. (4) Ursodeoxycholic acid (UDCA, an ER stress-reducing bile acid) will prevent fasting-induced pem-like deterioration in a placebo-controlled challenge trial.
Limitations. IEC UPR has never been studied in ME/CFS. Organoid cultures from ME/CFS patients do not exist. The fasting-UPR-gut-liver chain relies on general cell biology (well-established in other contexts) but has no ME/CFS-specific evidence. Patient reports of fasting effects are anecdotal; no controlled study of fasting in ME/CFS exists. The ER stress model predicts that fasting is detrimental in ME/CFS, but some patient reports suggest benefit — this may reflect inter-individual differences in mitochondrial reserve.
Certainty: 0.25. Bao et al. (2026) demonstrated that the gut microbiome contributes to systemic specialised pro-resolving mediator (SPM) pools by supplying precursor polyunsaturated fatty acids (PUFAs) and regulating host enzymes involved in SPM biosynthesis (Bao et al. 2026). If ME/CFS gut dysbiosis reduces the supply of bacterial-derived SPM precursors (short-chain fatty acid-conjugated PUFAs, microbially modified linoleic acid derivatives), the host’s capacity to produce resolving lipid mediators (resolvins, maresins, protectins) would be impaired, contributing to chronic non-resolving inflammation.
Mechanism. Gut bacteria — particularly Firmicutes (Lactobacillus, Faecalibacterium, Roseburia) and Bacteroidetes — metabolise dietary PUFAs (linoleic acid, alpha-linolenic acid) into conjugated linoleic acids (CLAs), hydroxy fatty acids, and other bioactive lipids. These bacterial PUFA metabolites enter the host circulation and serve as substrates for: (1) host LOX and COX enzymes for resolvin and maresin synthesis; (2) regulation of host PUFA desaturase expression (FADS1, FADS2) via PPAR-gamma signalling — linking directly to the FADS polymorphisms discussed in Chapter Genetic and Epigenetic Factors (Speculation FADS1/2 Polymorphisms and SPM Precursor Conversion in ME/CFS). If butyrate-producing bacteria (F. prausnitzii, E. rectale, Roseburia) — all reduced in ME/CFS (Section Gut Microbiome Alterations) — are also the primary source of bacterial PUFA metabolites, their depletion would produce a dual deficit: insufficient SPM precursors AND reduced PPAR-gamma activation. The combined deficit impairs both SPM biosynthesis and the transcriptional machinery needed for SPM production.
ME/CFS context. SPM deficiency could explain the chronic, non-resolving inflammation profile in ME/CFS (Chapter Immune System Dysfunction): inflammation is activated normally but fails to resolve because the SPM resolution programme lacks precursor substrate. This differs from classical SPM deficiency models where the failure is enzymatic (defective LOX/COX pathways) — here the failure is microbial substrate supply, which is potentially correctable by microbiome-targeted interventions (probiotics, prebiotics, dietary PUFA modulation).
Falsifiable predictions. (1) ME/CFS plasma will show reduced SPM levels (LC-MS/MS: resolvin D1, maresin 1, protectin D1) compared to controls, with the deficit correlating with reduced Faecalibacterium and Roseburia abundance. (2) ME/CFS plasma will show altered PUFA metabolite profiles (reduced CLAs, reduced hydroxy-octadecadienoic acids) consistent with reduced bacterial PUFA metabolism. (3) Fecal microbiome transplantation from healthy donors, or targeted prebiotic supplementation (inulin, FOS), will increase bacterial PUFA metabolites in ME/CFS plasma and partially restore SPM levels. (4) SPM levels will correlate inversely with PEM severity: patients with the lowest resolvin D1 will show the most severe post-exertional symptom exacerbations.
Limitations. The Bao et al. (2026) finding that the microbiome contributes to systemic SPM pools has not been replicated in any disease cohort, let alone ME/CFS. SPM measurement (LC-MS/MS) is technically demanding and not clinically available. The specific bacteria responsible for PUFA metabolite production in humans are incompletely characterised. Even if SPM deficiency is confirmed, its contribution to ME/CFS inflammation relative to other mechanisms (cGAS-STING, complement, NLRP3) is unknown.